Want to see TSE:AVCR full AI Analyst Report?
Avricore Health (AVCR) AI Stock Analysis
Avricore Health
(TSXV:AVCR)
The score is primarily driven down by weak financial performance—negative gross profit, widening losses, and negative operating/free cash flow in the TTM period—despite the benefit of having essentially no debt. Technicals add further pressure as the stock trades below major moving averages with negative MACD and weak RSI, while valuation is difficult to justify with negative earnings and no dividend yield support.
Avricore Health (AVCR) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 81.03K
- Dividend Yield
- ―
- Average Volume (3M)
- 61.82K
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 1.31
- Revenue Growth
- -93.73%
- EPS Growth
- -25.53%
- Country
- Canada
- Employees
- 26
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Avricore Health Business Overview & Revenue Model
Company Description
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies...
How the Company Makes Money
Avricore Health primarily makes money by commercializing its pharmacy-based POCT ecosystem centered on the HealthTab platform. Revenue is generated from (1) fees tied to the deployment and ongoing use of HealthTab by pharmacies (e.g., platform/softwa...
Avricore Health Financial Statement Overview
Summary
Weak operating profile in the most recent period: TTM revenue is very low, gross profit is negative, losses have widened, and both operating cash flow and free cash flow are negative. The main offset is a clean capital structure with essentially no debt, but profitability and cash consumption materially increase execution and funding risk.
Income Statement
18Very NegativeBalance Sheet
54NeutralCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 193.04K | 533.88K | 4.79M | 3.49M | 1.77M | 122.81K |
| Gross Profit | -70.94K | 236.33K | 1.88M | 1.20M | 456.79K | 30.52K |
| EBITDA | -1.23M | -1.23M | -208.44K | -275.14K | -629.76K | -1.64M |
| Net Income | -1.80M | -1.86M | -668.98K | -701.22K | -818.23K | -1.71M |
Balance Sheet | ||||||
| Total Assets | 1.24M | 563.13K | 2.30M | 2.54M | 2.57M | 2.28M |
| Cash, Cash Equivalents and Short-Term Investments | 922.55K | 237.92K | 1.14M | 286.57K | 630.53K | 2.01M |
| Total Debt | 0 | 0 | 0 | 40.00K | 40.00K | 40.00K |
| Total Liabilities | 129.17K | 173.56K | 330.82K | 529.22K | 604.89K | 84.48K |
| Stockholders Equity | 1.11M | 389.56K | 1.97M | 2.01M | 1.96M | 2.20M |
Cash Flow | ||||||
| Free Cash Flow | -1.13M | -904.29K | 799.27K | -386.46K | -1.64M | -1.37M |
| Operating Cash Flow | -1.10M | -789.93K | 1.00M | 660.40K | -437.83K | -1.23M |
| Investing Cash Flow | -29.20K | -114.36K | -205.35K | -1.05M | -1.21M | -140.36K |
| Financing Cash Flow | 1.19M | 0 | 56.60K | 42.50K | 253.88K | 3.08M |
Avricore Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AVCR, the sentiment is Negative. The current price of 0.05 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.06, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 43.59 is Neutral, neither overbought nor oversold. The STOCH value of 21.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AVCR.
Avricore Health Risk Analysis
Avricore Health disclosed 18 risk factors in its most recent earnings report. Avricore Health reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksAvricore Health Peers Comparison
Overall Rating
TSE:TELO46Neutral- TSE:AVCR44Neutral
TSE:BUX40Underperform
TSE:NARA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:TELO | 46Neutral | CAD 5.02M | -2.17 | 295.03% | ― | ― | 25.57% |
| TSE:AVCR | 44Neutral | CAD 6.32M | -2.84 | -241.33% | ― | -93.73% | -25.53% |
| TSE:BUX | 40Underperform | CAD 50.05M | -34.81 | -250.77% | ― | -82.05% | 23.73% |
| TSE:NARA | 38Underperform | CAD 2.39M | -0.82 | 184.91% | ― | ― | 43.30% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:AVCR | Avricore Health | 0.05 | 0.00 | 0.00% | |
| TSE:BUX | BioMark Diagnostics | 0.47 | 0.13 | 38.24% | |
| TSE:TELO | Telo Genomics | 0.05 | 0.00 | 0.00% | |
| TSE:SZLS.H | Stagezero Life Sciences | 0.04 | 0.00 | 0.00% | |
| TSE:NARA | PanGenomic Health, Inc. Class A | 0.17 | -1.03 | -85.83% |
Avricore Health Corporate Events
Avricore’s HealthTab Links AI Retinal Screening to U.K. Community Pharmacies
PositiveAvricore Health’s HealthTab platform has been integrated with HeartEye, a U.K. provider of AI-based retinal cardiovascular risk assessment, creating a new referral pathway from opticians to community pharmacies. Patients flagged at elevated car...
Avricore’s HealthTab Wins National NHS Role in England’s Pharmacy Cholesterol Drive
PositiveNHS England has approved a national rollout of the Barts Health pharmacy cholesterol testing initiative using Avricore’s HealthTab platform. Around 100 pharmacies across England will begin offering seven-minute cholesterol checks this fall, ext...
Avricore Grants Stock Options as HealthTab PoCT Platform Expands and Tightens Quality Controls
PositiveAvricore Health has granted stock options exercisable for 3,300,000 common shares at an exercise price of CAD $0.06 to its directors, officers, employees, and consultants under its stock option plan, with options vesting quarterly and expiring five y...
Avricore’s HealthTab Strikes Landmark UK Point-of-Care Testing Deal with Abbott
PositiveAvricore Health’s subsidiary HealthTab has signed a multi-year collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products through the HealthTab platform across the U.K. pharmacy network. The deal...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026